Press Releases

Month Year

Month Year

Feb 12, 2021

Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021

Read more
Feb 5, 2021

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jan 5, 2021

Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Read more
Jan 4, 2021

Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

--First Patient Dosed in Post-Marketing Program Intended to Support Full FDA Approval of ARIKAYCE and sNDA in Newly Diagnosed Patients--

Read more
Dec 4, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Dec 2, 2020

Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

--First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--

Read more
Nov 24, 2020

Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference

Read more
Nov 13, 2020

Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Read more
Nov 6, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Nov 2, 2020

Insmed to Present at Two November Conferences

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation